{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:12:07Z","timestamp":1772208727415,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,22]]},"DOI":"10.7759\/cureus.27132","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T09:51:21Z","timestamp":1658483481000},"source":"Crossref","is-referenced-by-count":3,"title":["Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease?"],"prefix":"10.7759","author":[{"given":"Mastiyage R","family":"Goonathilake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Waqar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheeba","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilford","family":"Jean-Baptiste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amina","family":"Yusuf Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bithaiah","family":"Inyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feeba Sam","family":"Koshy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kitty","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakar","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roopa","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1201\/9781003046547","article-title":"Chronic lung diseases: treatment, challenges, and solutions","author":"Das A","year":"2021","unstructured":"Das A, Saikia R, Pathak K, Gogoi U, Saikia S. Chronic lung diseases: treatment, challenges, and solutions. Handbook of Lung Targeted Drug Delivery Systems: Recent Trends and Clinical Evidences. Pathak Y, Islam N (ed): CRC Press, London, UK; 2021. 10.1201\/9781003046547"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30105-3","article-title":"Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"8","year":"2020","unstructured":"Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017. a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020, 8:585-96. 10.1016\/S2213-2600(20)30105-3","journal-title":"Lancet Respir Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30157-0","article-title":"Chronic respiratory diseases: a global view","volume":"8","author":"Labaki WW","year":"2020","unstructured":"Labaki WW, Han MK. Chronic respiratory diseases: a global view. Lancet Respir Med. 2020, 8:531-3. 10.1016\/S2213-2600(20)30157-0","journal-title":"Lancet Respir Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15095","article-title":"Cyclic AMP in dendritic cells: a novel potential target for disease-modifying agents in asthma and other allergic disorders","volume":"177","author":"Chinn AM","year":"2020","unstructured":"Chinn AM, Insel PA. Cyclic AMP in dendritic cells: a novel potential target for disease-modifying agents in asthma and other allergic disorders. Br J Pharmacol. 2020, 177:3363-77. 10.1111\/bph.15095","journal-title":"Br J Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.740803","article-title":"Tanimilast, a novel inhaled Pde4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease","volume":"12","author":"Facchinetti F","year":"2021","unstructured":"Facchinetti F, Civelli M, Singh D, Papi A, Emirova A, Govoni M. Tanimilast, a novel inhaled Pde4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Front Pharmacol. 2021, 12:740803. 10.3389\/fphar.2021.740803","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.518345","article-title":"Phosphodiesterase-4 inhibitors for non-COPD respiratory diseases","volume":"12","author":"Kawamatawong T","year":"2021","unstructured":"Kawamatawong T. Phosphodiesterase-4 inhibitors for non-COPD respiratory diseases. Front Pharmacol. 2021, 12:518345. 10.3389\/fphar.2021.518345","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2022.2026328","article-title":"Phosphodiesterase\u20114 inhibitors: a review of current developments (2013-2021)","volume":"32","author":"Liu Z","year":"2022","unstructured":"Liu Z, Liu M, Cao Z, Qiu P, Song G. Phosphodiesterase\u20114 inhibitors: a review of current developments (2013-2021). Expert Opin Ther Pat. 2022, 32:261-78. 10.1080\/13543776.2022.2026328","journal-title":"Expert Opin Ther Pat"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00259","article-title":"Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases","volume":"11","author":"Phillips JE","year":"2020","unstructured":"Phillips JE. Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases. Front Pharmacol. 2020, 11:259. 10.3389\/fphar.2020.00259","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13276","article-title":"Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: a systematic review and meta-analysis","volume":"23","author":"Luo J","year":"2018","unstructured":"Luo J, Yang L, Yang J, et al.. Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: a systematic review and meta-analysis. Respirology. 2018, 23:467-77. 10.1111\/resp.13276","journal-title":"Respirology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01135","article-title":"Phosphodiesterase 4 inhibitors in allergic rhinitis\/rhinosinusitis","volume":"11","author":"Janosova V","year":"2020","unstructured":"Janosova V, Calkovsky V, Pedan H, Behanova E, Hajtman A, Calkovska A. Phosphodiesterase 4 inhibitors in allergic rhinitis\/rhinosinusitis. Front Pharmacol. 2020, 11:1135. 10.3389\/fphar.2020.01135","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.33086\/jhs.v14i3.2114","article-title":"Roflumilast: review of phosphodiesterase-4 inhibitor as asthma therapy","volume":"29","author":"Syfridiana R","year":"2021","unstructured":"Syfridiana R, Herawati F. Roflumilast: review of phosphodiesterase-4 inhibitor as asthma therapy. J Health Sci. 2021, 29:214-21. 10.33086\/jhs.v14i3.2114","journal-title":"J Health Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.02.002","article-title":"Phosphodiesterases as therapeutic targets for respiratory diseases","volume":"197","author":"Zuo H","year":"2019","unstructured":"Zuo H, Cattani-Cavalieri I, Musheshe N, Nikolaev VO, Schmidt M. Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther. 2019, 197:225-42. 10.1016\/j.pharmthera.2019.02.002","journal-title":"Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li H","year":"2018","unstructured":"Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018, 9:1048. 10.3389\/fphar.2018.01048","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S242961","article-title":"New avenues for phosphodiesterase inhibitors in asthma","volume":"13","author":"Matera MG","year":"2021","unstructured":"Matera MG, Ora J, Cavalli F, Rogliani P, Cazzola M. New avenues for phosphodiesterase inhibitors in asthma. J Exp Pharmacol. 2021, 13:291-302. 10.2147\/JEP.S242961","journal-title":"J Exp Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101814","article-title":"Efficacy and safety of a first-in-class inhaled PDE3\/4 inhibitor (ensifentrine) vs salbutamol in asthma","volume":"58","author":"Bjermer L","year":"2019","unstructured":"Bjermer L, Abbott-Banner K, Newman K. Efficacy and safety of a first-in-class inhaled PDE3\/4 inhibitor (ensifentrine) vs salbutamol in asthma. Pulm Pharmacol Ther. 2019, 58:101814. 10.1016\/j.pupt.2019.101814","journal-title":"Pulm Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2021.0051","article-title":"Efficacy of roflumilast in bronchiectasis patients with frequent exacerbations: a double-blinded, randomized, placebo-controlled pilot clinical trial","volume":"85","author":"Juthong S","year":"2022","unstructured":"Juthong S, Panyarath P. Efficacy of roflumilast in bronchiectasis patients with frequent exacerbations: a double-blinded, randomized, placebo-controlled pilot clinical trial. Tuberc Respir Dis (Seoul). 2022, 85:67-73. 10.4046\/trd.2021.0051","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.03.116","article-title":"Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases","volume":"9","author":"Kawamatawong T","year":"2017","unstructured":"Kawamatawong T. Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J Thorac Dis. 2017, 9:1144-54. 10.21037\/jtd.2017.03.116","journal-title":"J Thorac Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031209","article-title":"Clinical implication of phosphodiesterase-4-inhibition","volume":"23","author":"Schick MA","year":"2022","unstructured":"Schick MA, Schlegel N. Clinical implication of phosphodiesterase-4-inhibition. Int J Mol Sci. 2022, 23:1209. 10.3390\/ijms23031209","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0191OC","article-title":"Roflumilast N-oxide in combination with formoterol enhances the antiinflammatory effect of dexamethasone in airway smooth muscle cells","volume":"56","author":"Patel BS","year":"2017","unstructured":"Patel BS, Rahman MM, Baehring G, Xenaki D, Tang FS, Oliver BG, Ammit AJ. Roflumilast N-oxide in combination with formoterol enhances the antiinflammatory effect of dexamethasone in airway smooth muscle cells. Am J Respir Cell Mol Biol. 2017, 56:532-8. 10.1165\/rcmb.2016-0191OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2018.1455858","article-title":"Burden of asthma among patients adherent to ICS\/LABA: a real-world study","volume":"56","author":"Davis J","year":"2019","unstructured":"Davis J, Trudo F, Siddall J, Small M. Burden of asthma among patients adherent to ICS\/LABA: a real-world study. J Asthma. 2019, 56:332-40. 10.1080\/02770903.2018.1455858","journal-title":"J Asthma"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-140","article-title":"Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects","volume":"12","author":"Gauvreau GM","year":"2011","unstructured":"Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, et al.. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res. 2011, 12:140. 10.1186\/1465-9921-12-140","journal-title":"Respir Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.04.023","article-title":"Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions","volume":"116","author":"van Schalkwyk E","year":"2005","unstructured":"van Schalkwyk E, Strydom K, Williams Z, et al.. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol. 2005, 116:292-8. 10.1016\/j.jaci.2005.04.023","journal-title":"J Allergy Clin Immunol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.11.035","article-title":"Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma","volume":"138","author":"Bateman ED","year":"2016","unstructured":"Bateman ED, Goehring UM, Richard F, Watz H. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. J Allergy Clin Immunol. 2016, 138:142-9.e8. 10.1016\/j.jaci.2015.11.035","journal-title":"J Allergy Clin Immunol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106906","article-title":"Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS","volume":"88","author":"Bodkhe S","year":"2020","unstructured":"Bodkhe S, Nikam M, Sherje AP, Khan T, Suvarna V, Patel K. Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS. Int Immunopharmacol. 2020, 88:106906. 10.1016\/j.intimp.2020.106906","journal-title":"Int Immunopharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.12703\/P7-16","article-title":"Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases","volume":"7","author":"Giembycz MA","year":"2015","unstructured":"Giembycz MA, Newton R. Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases. F1000Prime Rep. 2015, 7:16. 10.12703\/P7-16","journal-title":"F1000Prime Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-11-26","article-title":"The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma","volume":"11","author":"Singh D","year":"2010","unstructured":"Singh D, Petavy F, Macdonald AJ, Lazaar AL, O'Connor BJ. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res. 2010, 11:26. 10.1186\/1465-9921-11-26","journal-title":"Respir Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2016.06.011","article-title":"A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients","volume":"40","author":"Singh D","year":"2016","unstructured":"Singh D, Leaker B, Boyce M, et al.. A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients. Pulm Pharmacol Ther. 2016, 40:1-6. 10.1016\/j.pupt.2016.06.011","journal-title":"Pulm Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-14-166","article-title":"The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma","volume":"14","author":"Leaker BR","year":"2014","unstructured":"Leaker BR, Singh D, Ali FY, Barnes PJ, O'Connor B. The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014, 14:166. 10.1186\/1471-2466-14-166","journal-title":"BMC Pulm Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.06.007","article-title":"Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients","volume":"113","author":"Southworth T","year":"2019","unstructured":"Southworth T, Kaur M, Hodgson L, Facchinetti F, Villetti G, Civelli M, Singh D. Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients. Cytokine. 2019, 113:68-73. 10.1016\/j.cyto.2018.06.007","journal-title":"Cytokine"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0095-2019","article-title":"The future of bronchodilation: looking for new classes of bronchodilators","volume":"28","author":"Cazzola M","year":"2019","unstructured":"Cazzola M, Rogliani P, Matera MG. The future of bronchodilation: looking for new classes of bronchodilators. Eur Respir Rev. 2019, 28:190095. 10.1183\/16000617.0095-2019","journal-title":"Eur Respir Rev"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1571581","article-title":"New drugs in early-stage clinical trials for allergic rhinitis","volume":"28","author":"Heffler E","year":"2019","unstructured":"Heffler E, Brussino L, Del Giacco S, et al.. New drugs in early-stage clinical trials for allergic rhinitis. Expert Opin Investig Drugs. 2019, 28:267-73. 10.1080\/13543784.2019.1571581","journal-title":"Expert Opin Investig Drugs"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2013.02.007","article-title":"Pre-clinical studies in cough research: role of transient receptor potential (TRP) channels","volume":"26","author":"Grace MS","year":"2013","unstructured":"Grace MS, Dubuis E, Birrell MA, Belvisi MG. Pre-clinical studies in cough research: role of transient receptor potential (TRP) channels. Pulm Pharmacol Ther. 2013, 26:498-507. 10.1016\/j.pupt.2013.02.007","journal-title":"Pulm Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2018.01.008","article-title":"Inhibitors of phosphodiesterases in the treatment of cough","volume":"257","author":"Mokry J","year":"2018","unstructured":"Mokry J, Urbanova A, Kertys M, Mokra D. Inhibitors of phosphodiesterases in the treatment of cough. Respir Physiol Neurobiol. 2018, 257:107-14. 10.1016\/j.resp.2018.01.008","journal-title":"Respir Physiol Neurobiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1096\/fj.13-240861","article-title":"Anchored PDE4 regulates chloride conductance in wild-type and \u0394F508-CFTR human airway epithelia","volume":"28","author":"Blanchard E","year":"2014","unstructured":"Blanchard E, Zlock L, Lao A, et al.. Anchored PDE4 regulates chloride conductance in wild-type and \u0394F508-CFTR human airway epithelia. FASEB J. 2014, 28:791-801. 10.1096\/fj.13-240861","journal-title":"FASEB J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107826","article-title":"Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis","volume":"224","author":"Turner MJ","year":"2021","unstructured":"Turner MJ, Abbott-Banner K, Thomas DY, Hanrahan JW. Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis. Pharmacol Ther. 2021, 224:107826. 10.1016\/j.pharmthera.2021.107826","journal-title":"Pharmacol Ther"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.702677","article-title":"Type-4 phosphodiesterase (PDE4) blockade reduces NETosis in cystic fibrosis","volume":"12","author":"Totani L","year":"2021","unstructured":"Totani L, Amore C, Piccoli A, et al.. Type-4 phosphodiesterase (PDE4) blockade reduces NETosis in cystic fibrosis. Front Pharmacol. 2021, 12:702677. 10.3389\/fphar.2021.702677","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/99392-can-phosphodiesterase-4-inhibitor-therapy-be-used-in-respiratory-diseases-other-than-chronic-obstructive-pulmonary-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:34Z","timestamp":1707507394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/99392-can-phosphodiesterase-4-inhibitor-therapy-be-used-in-respiratory-diseases-other-than-chronic-obstructive-pulmonary-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.27132","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,22]]}}}